Problem

Ovarian cancer is the deadliest of all gynecologic cancers. With a five-year survival rate of only 46.5%, ovarian cancer claims the lives of more than 15K women each year in the United States alone.

This high mortality is attributed to the late-stage diagnosis of most ovarian cancer, partially due to a lack of high-performing, readily available diagnostic tools.

But, there is hope with PROMISS^®.

With early-stage detection, survival rates increase from 17% at stage four diagnosis to 92% when detected at stage one. This is why we’ve made it our mission to provide a globally accessible, non-invasive, precise diagnostic test for ovarian cancer that will detect cancer early and help save lives-- PROMISS^®.

Our Technology

Our company PROMISS^® Diagnostics is developing an innovative, machine-learning based clinical diagnostic test for ovarian cancer: PROMISS^® (Predicting Risk of Ovarian Malignancy In Serum Samples). The PROMISS^® test utilizes well-characterized, objective parameters in a proprietary algorithm to provide a concise score that indicates the presence of ovarian cancer.

The algorithm inputs are readily available, rendering it a low-cost, highly accurate, point-of-care diagnostic tool that can be widely-accessible and especially useful in low resource areas.

This proprietary diagnostic tool will enable clinicians to accurately distinguish benign from malignant masses in women presenting with adnexal (pelvic) masses at early stages.